Filing Details

Accession Number:
0001209191-23-030621
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-05-18 16:16:57
Reporting Period:
2023-05-16
Accepted Time:
2023-05-18 16:16:57
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1894562 Prime Medicine Inc. PRME Services-Computer Programming, Data Processing, Etc. (7370) DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1652044 Alphabet Inc. 1600 Amphitheatre Parkway
Mountain View CA 94043
No No Yes No
1845038 Gv 2019 Gp, L.l.c. 1600 Amphitheatre Parkway
Mountain View CA 94043
No No Yes No
1845039 Gv 2019 Gp, L.p. 1600 Amphitheatre Parkway
Mountain View CA 94043
No No Yes No
1845041 Gv 2019, L.p. 1600 Amphitheatre Parkway
Mountain View CA 94043
No No Yes No
1861202 Gv 2021, L.p. 1600 Amphitheatre Parkway
Mountain View CA 94043
No No Yes No
1861206 Gv 2021 Gp, L.l.c. 1600 Amphitheatre Parkway
Mountain View CA 94043
No No Yes No
1861216 Gv 2021 Gp, L.p. 1600 Amphitheatre Parkway
Mountain View CA 94043
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-05-16 50,649 $12.59 10,750,324 No 4 S Indirect By GV 2019, L.P.
Common Stock Disposition 2023-05-17 15,000 $12.77 10,735,324 No 4 S Indirect By GV 2019, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By GV 2019, L.P.
No 4 S Indirect By GV 2019, L.P.
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,762,440 Indirect By GV 2021, L.P.
Footnotes
  1. This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.465 to $12.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 and in footnote 4 of this Form 4.
  3. The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.95 to $13.075, inclusive.
  5. The securities reported in this row are directly beneficially owned by GV 2021, L.P. (the "2021 Partnership"). The general partner of the 2021 Partnership is GV 2021 GP, L.P. (the "2021 GP"). The general partner of the 2021 GP is GV 2021 GP, L.L.C. ("GV 2021 LLC"). The sole member of GV 2021 LLC is Alphabet Holdings. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of the 2021 GP, GV 2021 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) the securities directly beneficially owned by the 2021 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.